Company Overview and News
Recently, Monmouth Real Estate Investment Corporation (MNR - Free Report) purchased a newly-developed industrial property situated at 650 Braselton Parkway, Braselton, GA. The 373,750-square-foot building, which is built on 93 acres, has been acquired for approximately $61 million. Notably, this property has been net leased to FedEx Ground Packaging System, Inc., for a period of 15 years. FedEx Ground — a division of The FedEx Corporation (FDX - Free Report) — is a leading North American provider of ground small-package delivery services in the United States and Canada.
BRK.A MNR COLD KO FDX
Monmouth Real Estate Investment Corporation (MNR - Free Report) has shelled out nearly $47.2 million for the purchase of a new 265,318-square-foot industrial building at 6850 Weber Boulevard, N. Charleston, SC. Net-leased for 15 years to FedEx Ground Packaging System, this buyout marks the company’s fourth property in Charleston. The purchase of this industrial property, which is situated on around 50 acres, is a strategic fit.
HD MNR DRE PLDGP PLD CBG OXY CBRE
Between the four REIT team members, we met with over 50 REIT management teams at the June REITWeek conference.
BPY DCT KRC BXP TCO KRG UDR LSI TRNO EQR MAC AVB VNO EQIX FR FRT JBGS RVI JCAP SPG QTS WPG PEI REG SKT CXP EXR CONE COR ESS GGP EGP DDR MNR ROIC UE RPAI PLD KRLP OFC IRT REXR DLR LPT WRI ESRT
Monmouth Real Estate Investment Corporation (MNR - Free Report) has shelled out nearly $33.7 million for the purchase of a new 362,942-square-foot industrial building at 6735 Trippel Road, Theodore, AL. Net-leased for 11 years to Amazon Fulfillment Service, this buyout marks the company’s second property leased to Amazon. The purchase of this industrial property, which is situated on around 31.27 acres, in the Mobile, AL MSA, is a strategic fit.
MNR DRE PLDGP PLD CBG PII CBRE
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to MNR / Monmouth Real Estate Investment Corp. on message board site Silicon Investor.
as of ET